Categorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET study

Basit Öğe Kaydı
dc.contributor.authorGunen, Hakan
dc.contributor.authorYilmaz, Mehmet
dc.contributor.authorAktas, Oguz
dc.contributor.authorErgun, Pinar
dc.contributor.authorOrtakoylu, Mediha Gonenc
dc.contributor.authorDemir, Atike
dc.contributor.authorCetinkaya, Pelin
dc.contributor.authorGurgun, Alev
dc.contributor.authorOtlu, Muge
dc.contributor.authorCilli, Aykut
dc.contributor.authorYilmaz, Ufuk
dc.contributor.authorKokturk, Nurdan
dc.contributor.authorCandemir, Ipek
dc.contributor.authorYakar, Halil Ibrahim
dc.contributor.authorAr, Idilhan
dc.contributor.authorKonya, Aylin
dc.date.accessioned2019-10-27T22:29:09Z
dc.date.available2019-10-27T22:29:09Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: To determine distribution of COPD assessment categories and physicians' adherence to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 strategy in Turkish COPD patients. Methods: A total of 1,610 COPD patients (mean [standard deviation] age: 62.6 [9.9] years, 85.7% were males) were included in this multicenter, non-interventional, cross-sectional study. Patients were categorized via GOLD 2013 strategy document. Consistency between reported and re-classified GOLD categories, and measures used for symptom evaluation and exacerbation was analyzed. Results: Overall, 41.1% of patients were assigned to GOLD A, while 13.2% were assigned to GOLD C categories. Long-acting beta-2 agonist + long-acting muscarinic antagonist + inhaled corticosteroid regimen was the most common treatment (62.0%). Over-treatment was noted in > 70% of GOLD A, B, and C patients. A high consistency between measures of symptom evaluation (Kappa coefficient = 0.993, P < 0.0001) and a low-moderate consistency between exacerbation risk measures (Kappa coefficient = 0.237, P < 0.0001) were noted. Conclusion: Our findings revealed GOLD A as the most prevalent category in Turkish cohort of COPD patients. Group assignment was altered depending on the chosen measure for symptom and risk assessment. Physician non-adherence to treatment recommendations in GOLD 2013 document leading to over-treatment in patients assigned to GOLD A, B, and C categories was also detected.en_US
dc.description.sponsorshipNovartis Pharmaceuticals Turkeyen_US
dc.description.sponsorshipThe study is funded by Novartis Pharmaceuticals Turkey. We thank Cagla Ayhan, MD and Prof Sule Oktay, MD, PhD from KAPPA Consultancy Training Research Ltd, Istanbul who provided editorial support and Mehmet Berktas, MD, MICR from KAPPA Consultancy Training Research Ltd, Istanbul who performed statistical analysis funded by Novartis Pharmaceuticals Turkey.en_US
dc.identifier.doi10.2147/COPD.S87464en_US
dc.identifier.endpage2494en_US
dc.identifier.issn1178-2005
dc.identifier.pmid26622176en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage2485en_US
dc.identifier.urihttps://doi.org/10.2147/COPD.S87464
dc.identifier.urihttps://hdl.handle.net/11454/51051
dc.identifier.volume10en_US
dc.identifier.wosWOS:000366030500001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherDove Medical Press Ltden_US
dc.relation.ispartofInternational Journal of Chronic Obstructive Pulmonary Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectcombined COPD assessmenten_US
dc.subjectsymptomsen_US
dc.subjectexacerbation risken_US
dc.subjectphysician adherenceen_US
dc.subjectTurkeyen_US
dc.titleCategorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu